Pasithea therapeutics announces intention to commence a $4.0 million tender offer for its common stock at price of $0.70 per share in cash

Palo alto, calif. and miami, july 20, 2023 (globe newswire) -- pasithea therapeutics corp. (nasdaq: ktta) (“pasithea” or the “company”), a biotechnology company focused on the discovery, research, and development of innovative treatments for central nervous system (cns) disorders, today announced that its board of directors (the "board") has authorized the repurchase, through a $4.0 million tender offer ("tender offer"), of up to approximately 5.7 million shares of the company's outstanding common stock, at an anticipated cash purchase price of $0.70 per share.
KTTA Ratings Summary
KTTA Quant Ranking